An interventional study of Desmopressin Acetate and NO DESMOPRESSIN in Severe Renal Impairment, sponsored by Sindh Institute of Urology and Transplantation. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Sindh Institute of Urology and Transplantation · Not applicable, Interventional, and Prevention
This study evaluated whether giving desmopressin before a native kidney biopsy reduces bleeding complications in adults with severe renal impairment (eGFR \<30 mL/min/1.73 m²). Patients undergoing kidney biopsy were enrolled sequentially into two groups: a non-desmopressin group and a desmopressin group. Patients were monitored for 24 hours after biopsy for bleeding complications, including perinephric hematoma, a decrease in hemoglobin, blood in the urine, need for blood transfusion, and other complications. The study also evaluated whether desmopressin was associated with adverse effects such as low blood sodium levels.
This prospective sequential cohort study evaluated the association between prophylactic intranasal desmopressin use and bleeding complications following native kidney biopsy in adults with severe renal impairment. The study was conducted at the Sindh Institute of Urology and Transplantation (SIUT), Karachi, from October 2024 to September 2025. Adults aged 18 years or older with an estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m² who underwent native kidney biopsy for clinical indications were consecutively enrolled. Patients were sequentially enrolled into a non-desmopressin cohort from October 2024 to March 2025 and a desmopressin cohort from April 2025 to September 2025. All patients underwent ultrasound-guided kidney biopsy and were monitored clinically and by ultrasonography for 24 hours after the procedure. The study evaluated post-biopsy bleeding complications and safety outcomes, including perinephric hematoma, hemoglobin decline, gross hematuria, blood transfusion, invasive interventions, and changes in serum sodium.
1,409 studies on the registry are indexed under Renal Insufficiency; 143 are open to participants now.
This study's enrollment of 250 is above the median of 40 across 1,058 interventional studies indexed under Renal Insufficiency.
Browse Renal Insufficiency studies →Sindh Institute of Urology and Transplantation is the lead sponsor of 18 studies on the registry; 6 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:Adults aged 18 years or older who provided , had an estimated (eGFR) \<30 mL/min/1.73 m², and underwent native kidney for a clinical indication, irrespective of dialysis status.
-
Exclusion Criteria:Pregnant women, kidney transplant recipients, and patients with to kidney biopsy.
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergoing native kidney biopsy who did not receive prophylactic desmopressin. Patients were monitored for 24 hours after biopsy for bleeding complications and other safety outcomes.
Other: NO DESMOPRESSIN
Patients undergoing native kidney biopsy who received prophylactic intranasal desmopressin before the biopsy. Patients were monitored for 24 hours after biopsy for bleeding complications and other safety outcomes.
Drug: Desmopressin Acetate
Prophylactic intranasal desmopressin acetate administered before native kidney biopsy in adults with severe renal impairment (eGFR \<30 mL/min/1.73 m²). Patients were monitored for 24 hours after biopsy for bleeding complications and safety outcomes.
Overall bleeding complications after native kidney biopsy
Occurrence of any post-biopsy bleeding complication, including clinically relevant perinephric hematoma, hemoglobin decline ≥2 g/dL, persistent or clinically significant gross hematuria, or other clinically significant bleeding complications.
Time frame: Within 24 hours after kidney biopsy
Perinephric hematoma >5 cm, Hemoglobin decline ≥2 g/dL, Blood transfusion requirement, Hyponatremia
Assessment of post-biopsy bleeding and safety outcomes, including perinephric hematoma \>5 cm, hemoglobin decline ≥2 g/dL, clinically significant gross hematuria, blood transfusion requirement, and other clinically significant post-biopsy complications.
Time frame: Within 24 hours after kidney biopsy
Plan to share: No — Individual participant data will not be shared with other researchers.
No publications or documents are linked to this record.
Ran from Aug 2017 to primary completion in Nov 2017, 3 months.
Of 118 non-industry interventional studies with no phase under Renal Insufficiency, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's 3 months is below that.
Counting every sponsor, half of 149 studies reached it within 22 months; a quarter within 8 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Deamino Arginine Vasopressin
Sindh Institute of Urology and Transplantation